Susan E. Barrowcliffe
2018
In 2018, Susan E. Barrowcliffe earned a total compensation of $2M as General Manager, Europe at Aimmune Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $131,708 |
|---|---|
| Option Awards | $1,200,251 |
| Salary | $303,131 |
| Stock Awards | $319,406 |
| Total | $1,954,496 |
Barrowcliffe received $1.2M in option awards, accounting for 61% of the total pay in 2018.
Barrowcliffe also received $131.7K in non-equity incentive plan, $303.1K in salary and $319.4K in stock awards.
Rankings
In 2018, Susan E. Barrowcliffe's compensation ranked 5,872nd out of 14,244 executives tracked by ExecPay. In other words, Barrowcliffe earned more than 58.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,872 out of 14,244 | 59th |
Division Manufacturing | 2,227 out of 5,765 | 61st |
Major group Chemicals And Allied Products | 828 out of 2,128 | 61st |
Industry group Drugs | 691 out of 1,817 | 62nd |
Industry Pharmaceutical Preparations | 537 out of 1,391 | 61st |
Source: SEC filing on April 10, 2019.
Barrowcliffe's colleagues
We found five more compensation records of executives who worked with Susan E. Barrowcliffe at Aimmune Therapeutics in 2018.
2018
Jayson Dallas
Aimmune Therapeutics
Chief Executive Officer
2018
Douglas Sheehy
Aimmune Therapeutics
General Counsel
2018
Daniel Adelman
Aimmune Therapeutics
Chief Medical Officer
2018
Eric Bjerkholt
Aimmune Therapeutics
Chief Financial Officer
2018
Stephen Dilly
Aimmune Therapeutics